Immunologic classification of leukemia and lymphoma

Blood. 1986 Jul;68(1):1-31.

Abstract

Important insights into leukocyte differentiation and the cellular origins of leukemia and lymphoma have been gained through the use of monoclonal antibodies that define cell surface antigens and molecular probes that identify immunoglobulin and T cell receptor genes. Results of these studies have been combined with markers such as surface membrane and cytoplasmic immunoglobulin on B lymphocytes, sheep erythrocyte receptors on T lymphocytes, and cytochemical stains. Using all of the above markers, it is now clear that acute lymphoblastic leukemia (ALL) is heterogeneous. Furthermore, monoclonal antibodies that identify B cells, such as the anti-B1 and anti-B4 antibodies in combination with studies of immunoglobulin gene rearrangement, have demonstrated that virtually all cases of non-T-ALL are malignancies of B cell origin. At least six distinct subgroups of non-T-ALL can now be identified. T-ALL is subdivided by the anti-Leu-9, anti-Leu-1, and antibodies that separate T lymphocyte subsets into three primary subgroups. Monoclonal antibodies are also useful in the subclassification of non-Hodgkin's lymphoma, and certain distinct markers can be correlated with morphologic classification. The cellular origin of the malignant Reed-Sternberg cell in Hodgkin's disease remains uncertain. A substantial number of investigators favor a myelocyte/macrophage origin based on cytochemical staining; however, consistent reactivity with antimonocyte reagents has not been demonstrated. Although monoclonal antibodies are useful in distinguishing acute myeloid from acute lymphoid leukemias, they have less certain utility in the subclassification of acute myelogenous leukemia (AML). Attempts to subclassify AML by differentiation-associated antigens rather than by the French-American-British (FAB) classification are underway in order to document the potential prognostic utility of surface markers. Therapeutic trials using monoclonal antibodies in leukemia and lymphoma have been reported. Intravenous (IV) infusion of unlabeled antibodies is the most widely used method; transient responses have been demonstrated. Antibodies conjugated to radionuclides have been quite successful in localizing tumors of less than 1 cm in some studies. Therapy trials with antibodies conjugated to isotopes, toxins, and drugs are currently planned. Purging of autologous bone marrow with monoclonal antibodies and complement in vitro has been used in ALL and non-Hodgkin's lymphoma; preliminary data suggest that this approach may be an effective therapy and may circumvent many of the obstacles and toxicities associated with in vivo monoclonal antibody infusion.

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antigens, Neoplasm / analysis
  • Antigens, Surface / analysis
  • B-Lymphocytes / immunology
  • Histocompatibility Antigens Class II / analysis
  • Hodgkin Disease / classification
  • Humans
  • Leukemia / classification*
  • Leukemia / diagnosis
  • Leukemia / immunology
  • Leukemia, Lymphoid / classification
  • Leukemia, Myeloid / classification
  • Leukemia, Myeloid / pathology
  • Leukemia, Myeloid, Acute / classification
  • Leukemia, Myeloid, Acute / pathology
  • Lymphoma / classification*
  • Lymphoma / diagnosis
  • Lymphoma / immunology
  • Lymphoma, Non-Hodgkin / classification
  • Neprilysin
  • T-Lymphocytes / immunology

Substances

  • Antibodies, Monoclonal
  • Antigens, Neoplasm
  • Antigens, Surface
  • Histocompatibility Antigens Class II
  • Neprilysin